Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
befiradol (18F)
- Development stage
- Unknown
- Lead developer
- Neurolixis
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Befiradol (18F), also known as [18F]F15599, is a radiopharmaceutical PET (Positron Emission Tomography) tracer and a highly selective agonist for the serotonin 5-HT1A receptor. It is specifically designed to bind with high affinity to the G-protein-coupled (active) state of the 5-HT1A receptor, providing a functional measure of receptor density and activity in the brain. Developed originally by Pierre Fabre and currently utilized in clinical research by institutions such as Hospices Civils de Lyon, befiradol (18F) is used to investigate the neurobiology of conditions such as episodic cluster headache and major depressive disorder. By targeting the high-affinity state, it offers superior sensitivity compared to traditional 5-HT1A antagonists in detecting changes in serotonergic signaling within regions like the hypothalamus and raphe nuclei, which are critical in the pathophysiology of headache disorders.
- Other names
- 18F-befiradol[18F]-F15599
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on befiradol (18F).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on befiradol (18F).